Biotech - Spark Newswire

2 minute read

One Year Following Single Administration, UniQure’s Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels

Today, 8:24 PM

UniQure N.V. (NASDAQ:QURE) has announced 52-week data from its Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec to treat hemophilia…

QURE

1 minute read

Pear Therapeutics Plans To Go Public In $1.6B SPAC Deal

By Vandana Singh

Today, 8:24 PM

The digital treatment developer Pear Therapeutics is taking the SPAC route to go public through a deal expected to provide…

THMA

1 minute read

MediciNov Sees Volume After Zacks Research Raises Price Target To $28

By Vandana Singh

Today, 8:24 PM

MediciNov Inc (NASDAQ: MNOV) sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock price target to $28 from $26.5 earlier.

MNOV

2 minute read

Should Investors Be Worried About The Delta Strain Of COVID-19?

By Wayne Duggan

Today, 8:24 PM

The SPDR S&P 500 ETF Trust (NYSE: SPY) is up another 13% so far in the first half of 2021 as investors anticipate a full economic reopening this summer following the COVID-19 pandemic.

PFE

3 minute read

Nanomedicine Company Makes “Nanomachines” that Attack Viruses

By Kim Griffin

Today, 8:24 PM

Photo by Fusion Medical Animation on Unsplash

MRNA

2 minute read

NanoViricides Review: What you Need to Know About the Company

By Kim Griffin

Today, 8:24 PM

With the coronavirus changing the world in 2020, it makes sense that there’s a spotlight on science to prevent viruses from growing into pandemics. While Pfizer (NYSE: PFE) and Moderna Inc.

MRNA

1 minute read

UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition

By Vandana Singh

Today, 8:24 PM

UniQure N.V. (NASDAQ:QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common…

QURE

1 minute read

Galecto’s GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs

By Vandana Singh

Today, 8:24 PM

Amid the continued evolution of the COVID-19 landscape, Galecto Inc (NASDAQ:GLTO) said it would focus on the Phase 2 pipeline…

GLTO

1 minute read

TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19

By Vandana Singh

Today, 8:24 PM

Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ:TFFP) have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their…

TFFP